Objectives: The COVID-19 pandemic poses a significant economic burden on society worldwide. This burden consists of direct, indirect and intangible costs. In context of the health economics, in 2020 the greatest emphasis was placed on the costs of COVID-19 diagnostics and acute treatment. At the beginning of 2021, the challenge for the health economics is the costs and benefits of vaccination. At the same time, attention must be paid to the long-term consequences of COVID-19. The aim of this research is to forecast the expansion of a post-viral chronic fatigue syndrome (CFS) as a potential consequence of COVID-19 and its burden on society. Methods: The survey data were obtained from COVID-19 patients cohort established at the National Biob...
Previous efforts to estimate the burden of fatigue-related symptoms due to long COVID have a very hi...
BackgroundA substantial portion of people with COVID-19 subsequently experience lasting symptoms inc...
BackgroundThe global prevalence of PASC is estimated to be present in 0·43 and based on the WHO esti...
Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a poorly understood, comp...
Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.Background: Myalgic en...
Objectives: Fibromyalgia syndrome (FM) is a complex disease that is mainly characterised by chronic ...
OBJECTIVE: Characterization of the clinical features of patients with persistent symptoms after mild...
BackgroundThe global prevalence of PASC is estimated to be present in 0·43 and based on the WHO esti...
A subset of patients has long-lasting symptoms after mild to moderate Coronavirus disease 2019 (COVI...
A subset of patients has long-lasting symptoms after mild to moderate Coronavirus disease 2019 (COVI...
Objective: : Chronic Fatigue Syndrome, a condition characterised by extreme fatigue that is not expl...
The aim of this study was to describe the clinical evolution during 6 months of follow-up of adults ...
Objectives: to describe self-reported characteristics and symptoms of treatment-seeking patients wit...
Abstract Background Chronic fatigue syndrome (CFS) is a chronic incapacitating illness that affects ...
The House of Lords must alert the government about evidence showing that “long covid” (which include...
Previous efforts to estimate the burden of fatigue-related symptoms due to long COVID have a very hi...
BackgroundA substantial portion of people with COVID-19 subsequently experience lasting symptoms inc...
BackgroundThe global prevalence of PASC is estimated to be present in 0·43 and based on the WHO esti...
Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a poorly understood, comp...
Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.Background: Myalgic en...
Objectives: Fibromyalgia syndrome (FM) is a complex disease that is mainly characterised by chronic ...
OBJECTIVE: Characterization of the clinical features of patients with persistent symptoms after mild...
BackgroundThe global prevalence of PASC is estimated to be present in 0·43 and based on the WHO esti...
A subset of patients has long-lasting symptoms after mild to moderate Coronavirus disease 2019 (COVI...
A subset of patients has long-lasting symptoms after mild to moderate Coronavirus disease 2019 (COVI...
Objective: : Chronic Fatigue Syndrome, a condition characterised by extreme fatigue that is not expl...
The aim of this study was to describe the clinical evolution during 6 months of follow-up of adults ...
Objectives: to describe self-reported characteristics and symptoms of treatment-seeking patients wit...
Abstract Background Chronic fatigue syndrome (CFS) is a chronic incapacitating illness that affects ...
The House of Lords must alert the government about evidence showing that “long covid” (which include...
Previous efforts to estimate the burden of fatigue-related symptoms due to long COVID have a very hi...
BackgroundA substantial portion of people with COVID-19 subsequently experience lasting symptoms inc...
BackgroundThe global prevalence of PASC is estimated to be present in 0·43 and based on the WHO esti...